



College voor Zorgverzekeringen



| Van goede zorg verzekerd |



College voor Zorgverzekeringen

Impact of reimbursement policies on prudent use, availability and pipeline of new antibacterials

Ad Schuurman
London, 8th November



Quick review

- Short interviews 26 EU countries
- Competent Authorities
- Departments of Health
- Reimbursement organisations (assessment and payers)
- Actual, but not scientific



Results

- 20 have no reimbursement policies
- 4 (?) trust on doctors guidelines (some monitor doctor prescribing)
- 20 follow normal reimbursement procedures for AMB's
- 2 special committee has to approve reimbursement AMB (high price)
- 1 uses co payment
- 1 essential list AMB
- 10 committee rational use (information, monitoring, recommendation treatment)
- 2(?) promote innovation/investment
- 2 campagne to population



General aspects

- In patient: hospital policy (not transparent)
- Out patient: committees
- Veterinary system can be dangerous